To help resolve the uncertainty whether @entity3163 ( @entity7034 ) therapy should be given intermittently or continuously, we examined iliac crest bone biopsies (before and after treatment) and @entity174 rates in 35 intermittently treated (group I) and 69 continuously treated (group C) @entity1 ; all received @entity460 . The following statistically significant results were obtained. Reduction in @entity174 rate was similar in the two groups. Trabecular thickness and the structurally more important mineralized thickness increased only in group I. Group I also accumulated less excess osteoid (surface, volume). Mean osteoid thickness did not change in either group because of a bimodal distribution of wide seams with osteoblasts and double @entity803 labels, and thin seams without osteoblasts or labels. Osteoid was lamellar. Osteoid in abnormal sites (within bone marrow or bone, or around osteocytes) was found less frequently in group I. Adjusted apposition rate declined and mineralization lag time increased in both groups because of extended unlabelled osteoid seams. Erosion surface increased only in group C. @entity2681 was seen less frequently in group I; it was closely associated with osteoid in abnormal sites and correlated with osteoid surface. Extended osteoid surface may have forced osteoclasts to hollow out trabeculae, leaving the empty osteoid shell in marrow. @entity10545 and eroded surface and osteoid and @entity2681 in abnormal sites correlated with @entity79 in group C. We conclude that intermittent therapy is to be preferred because it (1) increased mineralized trabecular thickness, (2) did not cause @entity10545 and @entity2681 , (3) showed @entity10545 in abnormal sites and (4) led to a similar reduction in the @entity174 rate as did continuous treatment. The question of whether intermittency of therapy has some other effect independent of the cumulative dose of @entity1388 administered cannot be answered by this study.

Fewer bone histomorphometric abnormalities with intermittent than with continuous slow-release XXXX therapy.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3163 :: ('MESH:D012969', 'Chemical') :: ['sodium fluoride'] @entity174 :: ('MESH:D050723', 'Disease') :: ['fragility fracture', 'vertebral fracture'] @entity1388 :: ('MESH:D005459', 'Chemical') :: ['fluoride'] @entity2681 :: ('MESH:D014077', 'Disease') :: ['erosion', 'Hook and/or tunnel erosion'] @entity10545 :: ('MESH:D010017', 'Disease') :: ['less osteoid and erosion', 'Excess osteoid volume', 'excessive osteoid accumulation'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone fragility'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity7034 :: ('CHEBI:28741', 'Chemical') :: ['NaF'] @entity803 :: ('MESH:D013752', 'Chemical') :: ['tetracycline']
@entity3163 :: (MESH:D012969,Chemical) :: ['sodium fluoride']
